Clinical trial
Efficacy, Safety and Tolerability Study of TAK-583 in Subjects With Postherpetic…
NCT00377598 · Takeda, Industry · Completed
Key facts
| NCT number | NCT00377598 |
|---|---|
| Title | Efficacy, Safety and Tolerability Study of TAK-583 in Subjects With Postherpetic Neuralgia |
| Official title | A Phase 2, Double Blind, Placebo Controlled, Dose-Ranging Study in Subjects With Postherpetic Neuralgia (PHN) to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Four Doses of TAK-583, Compared With Placebo |
| Lead sponsor | Takeda, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Neuralgia, Postherpetic |
| Intervention type | Drug |
| Interventions | TAK-583, Placebo |
| Enrollment | 399 |
| Start date | Oct 1, 2006 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Sep 18, 2006 |
| Last update posted | Feb 2, 2012 |
| Countries | Australia, Bulgaria, Czechia, Germany, Netherlands, Poland, Russia, South Africa, United Kingdom |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: